^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiEn (rezvilutamide)

    i
    Other names: SHR3680, SHR 3680, SHR-3680
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Androgen receptor inhibitor
    Related drugs:
    Associations

    News

    Trials
    8d
    Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (clinicaltrials.gov)
    P2, N=192, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • apalutamide • triptorelin • goserelin acetate • AiRuiEn (rezvilutamide)
    9d
    OMPC-RPM: Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Fudan University
    New P2 trial
    |
    AiRuiEn (rezvilutamide)
    30d
    Rezvilutamide for High-Risk Prostate Cancer After Surgery (clinicaltrials.gov)
    P=N/A, N=33, Not yet recruiting, Fujian Medical University Union Hospital
    New trial
    |
    leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide)
    30d
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • risvutatug rezetecan (GSK5764227)
    2ms
    A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1/2 trial
    |
    Tazverik (tazemetostat) • AiRuiEn (rezvilutamide) • HRS-5041
    2ms
    An open,non randomized, multicenter clinical studies of rezvilutamide or standard androgen deprivation therapy as adjuvant therapy in prostate cancer patients with poor PSA control after radical prostatectomy (ChiCTR2500113670)
    P=N/A, N=50, Not yet recruiting, The First Bethune Hospital of Jilin University; The First Bethune Hospital of Jilin University
    New trial
    |
    AiRuiEn (rezvilutamide)
    3ms
    MA-PCa-III-021: A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=156, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AiRuiEn (rezvilutamide)
    4ms
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
    4ms
    A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=156, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    AiRuiEn (rezvilutamide)
    5ms
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • risvutatug rezetecan (GSK5764227)
    5ms
    Primary high-grade urothelial carcinoma of the prostate combined with acinar adenocarcinoma: first rare case report and treatment experience summary. (PubMed, Front Oncol)
    Postoperatively, a surgery combined with targeted and immunotherapy regimen was initiated: leuprorelin + rezvilutamide for the acinar adenocarcinoma and disitamab vedotin + toripalimab for the urothelial carcinoma. The protocol of surgery combined with targeted and immunotherapy offers a new treatment strategy for this rare malignancy. This study provides valuable insights for clinical diagnosis and management.
    Journal
    |
    GATA3 (GATA binding protein 3)
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide)
    6ms
    RWS-GU001: Real-world Study on Preoperative Application of Rezvilutamide (clinicaltrials.gov)
    P=N/A, N=115, Not yet recruiting, Shanghai Pudong New Area Gongli Hospital
    New trial • Real-world evidence
    |
    AiRuiEn (rezvilutamide)